摘要
目的研究急性冠脉综合征(ACS)患者经替格瑞洛治疗前后血栓弹力图(TEG)的变化特点。方法 89例ACS患者给予替格瑞洛抗血小板治疗1周前后,抽血查血栓弹力图,比较其前后变化特点。结果替格瑞洛治疗后1周较治疗前TEG指标均有所改善,主要表现为R、K值升高,MA值、α角和G值、CI减小,但差异均无统计学意义(P>0.05)。但AA途径、ADP受体途径的抑制率均有所升高,且与治疗前相比差异有统计学意义(P<0.01)。结论替格瑞洛是一种很有前景的抗血小板药物,可以适应ACS及介入术后患者个体化治疗的需要,使血小板抑制率达标,最终使更多患者获益。
Objective To research the change characteristics of thrombelastogram（TEG） in acute coronary syndrome（ACS） patients treated by ticagrelor. Methods A total of 89 ACS cases were treated by ticagrelor antiplatelet therapy for 1 week, The characteristics of thrombelastogram before and after treatment were compared. Results Compared with the index before treatment, the TEG index of ACS patients improved after ticagrelor treatment, such as increased R and K, and decreased MA, α-angle, G, and CI, but the differences had no statistical significance（P〉0.05）. Inhibiting rates through AA-passage and ADP receptor-passage were increased, and the difference had statistical significance, compared with that before treatment（P〉0.01）. Conclusion Ticagrelor is a promising anti-platelet drug and it is adaptable to individuation treatment of patients with ACS and interventional therapy. It can make inhibiting rate of platelet reach the standard and benefit patients.
出处
《中国实用医药》
2014年第33期30-32,共3页
China Practical Medicine
